05.14.13
Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
Read More
05.09.13
Syndax Pharmaceuticals to Commercialize First-in-Class Lung Cancer Treatment Developed at the University of Colorado
Read More
05.29.12
Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
Read More
05.16.12
Syndax Pharmaceuticals Appoints Luke Evnin, Ph.D. to Board of Directors
Read More
04.30.12
Syndax Pharmaceuticals Announces Publication of Entinostat Phase 2 Clinical Trial Data in Journal of Clinical Oncology
Read More
04.18.12
Syndax Pharmaceuticals Appoints Arlene Morris as CEO
Read More
04.09.12
Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
Read More
04.05.12
Syndax Pharmaceuticals Appoints Arthur M. Pappas to Board of Directors
Read More
03.29.12
Syndax Pharmaceuticals to Present at Upcoming Conferences
Read More
02.08.12
Syndax Pharmaceuticals Announces Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models
Read More
02.07.12
Syndax Pharmaceuticals to Present at Upcoming Conferences
Read More
01.05.12
Syndax Pharmaceuticals Signs Agreement with Ventana Medical Systems, Inc. to Develop Companion Diagnostic Test for Entinostat
Read More